Key result
Preoperative methylprednisolone (15 mg/kg), but not tirilazad mesylate, decreased proinflammatory mediators and increased anti-inflammatory IL-10 during cardiopulmonary bypass.
Why the study?
Does preoperative methylprednisolone or tirilazad mesylate reduce inflammation and alter immune function in patients undergoing conventional coronary surgery with cardiopulmonary bypass?
RCT (n=39)
Double-blind
Randomized
No
Does preoperative methylprednisolone or tirilazad mesylate reduce inflammation and alter immune function in patients undergoing conventional coronary surgery with cardiopulmonary bypass?
Preoperative methylprednisolone, but not tirilazad mesylate, shifts the immune response toward anti-inflammation during cardiopulmonary bypass, though at the cost of increased monocyte functional deficits.
Methylprednisolone may warrant consideration to modulate CPB inflammation; extends RCT biomarker data but leaves clinical outcomes open.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Volk et al. (2001) conducted an RCT in Coronary artery disease requiring surgery (n=39). Methylprednisolone or tirilazad mesylate vs. Placebo was evaluated on Circulating mediators and monocyte-based functions. Preoperative methylprednisolone (15 mg/kg), but not tirilazad mesylate, decreased proinflammatory mediators and increased anti-inflammatory IL-10 during cardiopulmonary bypass.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: